Annual report

Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥1.13T2025-04-01 → 2026-03-31Cons.Revenue IFRS
Revenue¥1.04T2024-04-01 → 2025-03-31Cons.Revenue IFRS
Revenue¥921.9bn2023-04-01 → 2024-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥820.2bn2022-04-01 → 2023-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥703.3bn2021-04-01 → 2022-03-31vCons.Revenue IFRS (5-year summary)
Operating income¥176.3bn2025-04-01 → 2026-03-31Cons.Operating profit loss IFRS
Operating income¥157.7bn2024-04-01 → 2025-03-31Cons.Operating profit loss IFRS
Profit before tax¥178.3bn2025-04-01 → 2026-03-31Cons.Profit loss before tax IFRS
Profit before tax¥154.6bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS
Profit before tax¥140.8bn2023-04-01 → 2024-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥116.1bn2022-04-01 → 2023-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥114.5bn2021-04-01 → 2022-03-31vCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥135.9bn2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥117.0bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥106.4bn2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥135.9bn2025-04-01 → 2026-03-31Cons.Profit loss IFRS
Net income¥117.0bn2024-04-01 → 2025-03-31Cons.Profit loss IFRS
Total assets¥2.31Tat 2026-03-31Cons.Assets IFRS
Total assets¥1.83Tat 2025-03-31Cons.Assets IFRS
Total assets¥1.83Tat 2024-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥1.60Tat 2023-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥1.47Tat 2022-03-31vCons.Total assets IFRS (5-year summary)
Total liabilities¥727.7bnat 2026-03-31Cons.Liabilities IFRS
Total liabilities¥459.9bnat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥1.58Tat 2026-03-31Cons.Equity IFRS
Net assets / equity¥1.37Tat 2025-03-31Cons.Equity IFRS
Net assets / equity¥1.33Tat 2024-03-31vCons.Equity IFRS
Equity (owners)¥1.58Tat 2026-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.37Tat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.33Tat 2024-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.11Tat 2023-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.01Tat 2022-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥280.5bnat 2026-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥221.9bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥204.9bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥205.3bnat 2022-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥230.9bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥210.8bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥146.3bn2023-04-01 → 2024-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥344.1bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥82.5bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.5bn2023-04-01 → 2024-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow¥155.5bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥108.8bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥62.1bn2023-04-01 → 2024-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥92.142025-04-01 → 2026-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥79.012024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥71.52023-04-01 → 2024-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥59.52022-04-01 → 2023-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥58.722021-04-01 → 2022-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥92.122025-04-01 → 2026-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥78.992024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥71.472023-04-01 → 2024-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥59.482022-04-01 → 2023-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥58.692021-04-01 → 2022-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥1,074.18at 2026-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥927.85at 2025-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥893.8at 2024-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥746.07at 2023-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥669.23at 2022-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio68.5%at 2026-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.8%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.5%at 2024-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE9.2%2025-04-01 → 2026-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.7%2024-04-01 → 2025-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.7%2023-04-01 → 2024-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2022-04-01 → 2023-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE9.5%2021-04-01 → 2022-03-31vCons.Rate of return on equity IFRS (5-year summary)
Employees31,185at 2026-03-31Cons.Number of employees
Employees30,689at 2025-03-31Cons.Number of employees
Employees30,591at 2024-03-31vCons.Number of employees
Employees30,207at 2023-03-31vCons.Number of employees
Employees28,294at 2022-03-31vCons.Number of employees
Revenue¥452.2bn2025-04-01 → 2026-03-31StandaloneNet sales
Revenue¥428.7bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥399.8bn2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥375.0bn2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥341.4bn2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥100.9bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥89.4bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥174.5bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥147.8bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥110.7bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥91.1bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥79.4bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥198.1bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax¥148.3bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥158.9bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income¥122.3bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥87.9bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥79.0bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥62.8bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥1.58Tat 2026-03-31StandaloneAssets
Total assets¥1.42Tat 2025-03-31StandaloneAssets
Total assets¥1.44Tat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥1.33Tat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥1.28Tat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥597.1bnat 2026-03-31StandaloneLiabilities
Total liabilities¥549.7bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥987.5bnat 2026-03-31StandaloneNet assets
Net assets / equity¥870.0bnat 2025-03-31StandaloneNet assets
Net assets / equity¥813.8bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥765.6bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥765.4bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥88.5bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥69.8bnat 2025-03-31StandaloneCash and deposits
EPS (basic)¥107.752025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥82.582024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥59.052023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥52.612022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥41.522021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥107.722025-04-01 → 2026-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥82.562024-04-01 → 2025-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥59.032023-04-01 → 2024-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.592022-04-01 → 2023-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥41.492021-04-01 → 2022-03-31vStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥302025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥262024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥442023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥402022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥342021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥669.07at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥589.54at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥547.68at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥513.67at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥505.54at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio62.3%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio61.2%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio56.6%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE17.1%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE14.5%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE11.1%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE10.3%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued1,480,559,000at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,480,559,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued745,348,000at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued747,682,000at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees5,736at 2026-03-31StandaloneNumber of employees
Employees5,633at 2025-03-31StandaloneNumber of employees
Employees5,554at 2024-03-31vStandaloneNumber of employees
Employees5,457at 2023-03-31vStandaloneNumber of employees
Employees5,377at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-04-01 → 2026-03-31¥924m
Reconciling Itemsreconcilingrevenue external2025-04-01 → 2026-03-31¥294m
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2026-03-31−¥1.5bn
Blood And Cell Technologies Companyreportable segmentcapex2025-04-01 → 2026-03-31¥21.7bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2026-03-316557 pure
Blood And Cell Technologies Companyreportable segmentrevenue external2025-04-01 → 2026-03-31¥231.0bn
Blood And Cell Technologies Companyreportable segmentsegment profit2025-04-01 → 2026-03-31¥33.6bn
Cardiac And Vascular Companyreportable segmentcapex2025-04-01 → 2026-03-31¥36.7bn
Cardiac And Vascular Companyreportable segmentemployeesat 2026-03-3117007 pure
Cardiac And Vascular Companyreportable segmentrevenue external2025-04-01 → 2026-03-31¥676.4bn
Cardiac And Vascular Companyreportable segmentsegment profit2025-04-01 → 2026-03-31¥164.0bn
Medical Care Solutions Companyreportable segmentcapex2025-04-01 → 2026-03-31¥36.7bn
Medical Care Solutions Companyreportable segmentemployeesat 2026-03-316331 pure
Medical Care Solutions Companyreportable segmentrevenue external2025-04-01 → 2026-03-31¥216.1bn
Medical Care Solutions Companyreportable segmentsegment profit2025-04-01 → 2026-03-31¥21.6bn
Terumo Organ Technologiesreportable segmentcapex2025-04-01 → 2026-03-31¥1.1bn
Terumo Organ Technologiesreportable segmentemployeesat 2026-03-31238 pure
Terumo Organ Technologiesreportable segmentrevenue external2025-04-01 → 2026-03-31¥8.0bn
Terumo Organ Technologiesreportable segmentsegment profit2025-04-01 → 2026-03-31¥1.7bn
—segment totalcapex2025-04-01 → 2026-03-31¥96.2bn
—segment totalrevenue external2025-04-01 → 2026-03-31¥1.13T
—segment totalsegment profit2025-04-01 → 2026-03-31¥220.9bn
Reconciling Itemsreconcilingcapex2024-04-01 → 2025-03-31¥2.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2025-03-31¥298m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥712m
Blood And Cell Technologies Companyreportable segmentcapex2024-04-01 → 2025-03-31¥17.8bn
Blood And Cell Technologies Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥200.3bn
Blood And Cell Technologies Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥26.5bn
Cardiac And Vascular Companyreportable segmentcapex2024-04-01 → 2025-03-31¥43.6bn
Cardiac And Vascular Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥624.4bn
Cardiac And Vascular Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥154.7bn
Medical Care Solutions Companyreportable segmentcapex2024-04-01 → 2025-03-31¥18.5bn
Medical Care Solutions Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥211.2bn
Medical Care Solutions Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥23.0bn
—segment totalcapex2024-04-01 → 2025-03-31¥79.8bn
—segment totalrevenue external2024-04-01 → 2025-03-31¥1.04T
—segment totalsegment profit2024-04-01 → 2025-03-31¥204.2bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2026-03-31287 pure
Cardiac And Vascular Companyreportable segmentemployeesat 2026-03-312128 pure
Medical Care Solutions Companyreportable segmentemployeesat 2026-03-312469 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,844
ItemContextValueUnit
Comprehensive income IFRS (5-year summary)Prior4YearDuration178394000000JPY
Comprehensive income IFRS (5-year summary)Prior3YearDuration176415000000JPY
Comprehensive income IFRS (5-year summary)Prior2YearDuration258816000000JPY
Comprehensive income IFRS (5-year summary)Prior1YearDuration106802000000JPY
Comprehensive income IFRS (5-year summary)CurrentYearDuration256934000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior4YearInstant1012313000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior3YearInstant1111063000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior2YearInstant1327090000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant1368535000000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentYearInstant1584509000000JPY
Total assets IFRS (5-year summary)Prior4YearInstant1473693000000JPY
Total assets IFRS (5-year summary)Prior3YearInstant1602225000000JPY
Total assets IFRS (5-year summary)Prior2YearInstant1831402000000JPY
Total assets IFRS (5-year summary)Prior1YearInstant1828393000000JPY
Total assets IFRS (5-year summary)CurrentYearInstant2312234000000JPY
Equity to asset ratio IFRS (5-year summary)Prior4YearInstant669.23
Equity to asset ratio IFRS (5-year summary)Prior3YearInstant746.07
Equity to asset ratio IFRS (5-year summary)Prior2YearInstant893.80
Equity to asset ratio IFRS (5-year summary)Prior1YearInstant927.85
Equity to asset ratio IFRS (5-year summary)CurrentYearInstant1074.18
Basic earnings loss per share IFRS (5-year summary)Prior4YearDuration58.72
Basic earnings loss per share IFRS (5-year summary)Prior3YearDuration59.50
Basic earnings loss per share IFRS (5-year summary)Prior2YearDuration71.50
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration79.01
Basic earnings loss per share IFRS (5-year summary)CurrentYearDuration92.14
Diluted earnings loss per share IFRS (5-year summary)Prior4YearDuration58.69
Diluted earnings loss per share IFRS (5-year summary)Prior3YearDuration59.48
Diluted earnings loss per share IFRS (5-year summary)Prior2YearDuration71.47
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration78.99
Diluted earnings loss per share IFRS (5-year summary)CurrentYearDuration92.12
Ratio of owners equity to gross assets IFRS (5-year summary)Prior4YearInstant0.687
Ratio of owners equity to gross assets IFRS (5-year summary)Prior3YearInstant0.693
Ratio of owners equity to gross assets IFRS (5-year summary)Prior2YearInstant0.725
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.748
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentYearInstant0.685
Rate of return on equity IFRS (5-year summary)Prior4YearDuration0.095
Rate of return on equity IFRS (5-year summary)Prior3YearDuration0.084
Rate of return on equity IFRS (5-year summary)Prior2YearDuration0.087
Rate of return on equity IFRS (5-year summary)Prior1YearDuration0.087
Rate of return on equity IFRS (5-year summary)CurrentYearDuration0.092
Price earnings ratio IFRS (5-year summary)Prior4YearDuration31.71
Price earnings ratio IFRS (5-year summary)Prior3YearDuration30.03
Price earnings ratio IFRS (5-year summary)Prior2YearDuration38.17
Price earnings ratio IFRS (5-year summary)Prior1YearDuration35.40
Price earnings ratio IFRS (5-year summary)CurrentYearDuration22.88
Cash flows from used in operating activities IFRS (5-year summary)Prior4YearDuration141467000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior3YearDuration117536000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior2YearDuration146330000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration210802000000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYearDuration230852000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2026-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass
balance sheet identitynon_consolidated 2026-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass